A Phase II Randomized Double-Blind Trial of Topical Tazarotene 0.1% Gel Versus Placebo Gel for the Prevention of Regorafenib-Induced Hand-Foot-Skin Reaction
Latest Information Update: 12 Feb 2024
At a glance
- Drugs Tazarotene (Primary)
- Indications Erythrodysaesthesia
- Focus Therapeutic Use
Most Recent Events
- 05 Dec 2022 Status changed from recruiting to discontinued.
- 17 Dec 2020 Planned End Date changed from 1 Mar 2022 to 1 Mar 2023.
- 17 Dec 2020 Planned primary completion date changed from 1 Oct 2021 to 1 Oct 2022.